Press Release

01.02.2017

New paper on iXip published

A collaborative study published in the journal Cancer Treatment and Research Communications evaluated the diagnostic performance of iXip, XEPTAGEN's novel index to detect prostate cancer, in a real clinical setting (available HERE).

The prospective multicenter study, authored by clinicians at the Urology Unit of the Academic Medical Center Hospital in Udine, the Department of Surgery in Camposampiero and Pordenone hospitals, the Department of Urology in Brescia and Belluno hospitals, and the Departments of Laboratory Medicine and Oncological, Surgical and Gastroenterological Sciences of Padua’s University, showed that iXip is an accurate predictor of prostate cancer and can reduce the number of prostate biopsies without missing any case of tumour. In addition, results reported in the study confirmed that higher values of iXip are associated with more aggressive cancer.

Based on the study’s findings, iXip may be used to reduce the amount of unnecessary prostate biopsies performed every year on men suspected of having prostate cancer, facilitating the identification of patients with a more aggressive tumor.